HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2020-08-19
$37.02
-0.89 (-2.35%)
last quote
Want the full multi-source brief on HRMY?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$37.02
High
$38.74
Low
$36.38
Previous close
$37.91
Fundamentals
Market cap
$2.16B
P/E (TTM)
11.89x
P/S (TTM)
2.25x
P/B
2.48x
Gross margin
75.42%
Operating margin
24.03%
Net margin
18.88%
Rev growth (YoY)
24.25%
EPS growth (YoY)
-0.38%
ROE
20.06%
52W high
$43.49
52W low
$25.90
Beta
0.92x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04todaybefore market
Q3 2026EPS est $1.16Rev est $278.5M
Recent SEC filings
CIK 1802665filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 5d
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 5d
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 6d
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
Yahoo · 6d
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 7d
Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
Harmony Biosciences remains under pressure since the company announced its CEO transition. Will an upcoming narcolepsy drug change that?
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial